• Something wrong with this record ?

Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening

J. Sláma, V. Dvořák, M. Trnková, A. Skřivánek, K. Hrabcová, P. Ovesná, M. Nováčková

. 2024 ; 33 (2) : 168-176. [pub] 20230921

Language English Country England, Great Britain

Document type Journal Article

OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007004
003      
CZ-PrNML
005      
20240423155641.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/CEJ.0000000000000844 $2 doi
035    __
$a (PubMed)37751376
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sláma, Jiří $u Department of Obstetrics, Gynecology and Neonatology, General University Hospital, 1 Medical Faculty, Charles University, Prague
245    10
$a Is phased implementation of HPV testing and triage with dual staining the way to transform organized cytology screening / $c J. Sláma, V. Dvořák, M. Trnková, A. Skřivánek, K. Hrabcová, P. Ovesná, M. Nováčková
520    9_
$a OBJECTIVE: The substantial material and legislative investments in establishing and maintaining cytological screening in the Czech Republic represent barriers to a direct transition to primary HPV screening. Therefore, the LIBUSE project was implemented to test the efficacy of phasing in HPV DNA testing as a co-test to cytology in routine screening of women >30 years of age. METHODS: Women aged 30 to 60 years who underwent regular annual Pap smears were co-tested for HPV DNA with selective 16/18 genotyping at 3-year intervals. All HPV 16/18-positive cases and/or cases with a severe abnormality in cytology were sent for colposcopy; HPV non-16/18-positive cases and LSILs were graded using p16/Ki67 dual-stain cytology, and positive cases were sent for colposcopy. RESULTS: Overall, 2409 patients were included. After the first combined screening (year 'zero') visit, 7.4% of women were HPV-positive and 2.0% were HPV16/18-positive; only 8 women had severe Pap smear abnormalities. Triage by dual staining was positive in 21.9% of cases (28/128). Biopsy confirmed 34 high-grade precancer lesions. At the second combined visit (year 'three'), the frequency of HPV infection (5.3% vs. 7.4%) frequency of HPV16/18 (1.1% vs. 2.0%), referrals for colposcopy (35 vs. 83), and biopsy verified high-grade lesions (5 vs. 34) were significantly lower (all P ≤ 0.001). CONCLUSION: The addition of HPV DNA testing with selective genotyping of HPV16/18 to existing cytology screening significantly increased the safety of the program. The gradual introduction of HPV testing was well received by healthcare professionals and patients, and can facilitate transformation of the cytology-based screening. ClinicalTrials.gov Identifier: NCT05578833.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dospělí $7 D000328
650    12
$a dysplazie děložního hrdla $x diagnóza $7 D002578
650    12
$a nádory děložního čípku $7 D002583
650    _2
$a lidský papilomavirus 16 $x genetika $7 D052162
650    12
$a infekce papilomavirem $7 D030361
650    _2
$a třídění pacientů $7 D014218
650    _2
$a lidský papilomavirus 18 $x genetika $7 D052161
650    _2
$a plošný screening $7 D008403
650    _2
$a Papanicolaouův test $7 D065006
650    _2
$a DNA $7 D004247
650    _2
$a barvení a značení $7 D013194
650    _2
$a časná detekce nádoru $7 D055088
650    _2
$a vaginální stěr $7 D014626
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořák, Vladimír $u Center for Outpatient Gynaecology and Primary Care, Brno
700    1_
$a Trnková, Markéta $u Unilabs Pathology, Prague
700    1_
$a Skřivánek, Aleš $u G-Center, Olomouc
700    1_
$a Hrabcová, Karolína $u Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Ovesná, Petra $u Institute of Biostatistics and Analyses, Brno, Czech Republic
700    1_
$a Nováčková, Martina $u Institute of Biostatistics and Analyses, Brno, Czech Republic
773    0_
$w MED00001604 $t European journal of cancer prevention $x 1473-5709 $g Roč. 33, č. 2 (2024), s. 168-176
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37751376 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155637 $b ABA008
999    __
$a ok $b bmc $g 2081166 $s 1216771
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 33 $c 2 $d 168-176 $e 20230921 $i 1473-5709 $m European journal of cancer prevention $n Eur J Cancer Prev $x MED00001604
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...